Exelixis (EXEL) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company overview and strategy

• Focuses on oncology, with cabozantinib as the lead agent approved for multiple cancers and a robust pipeline of next-generation agents.

• Strong financial performance, with Q2 global net product revenue of $618 million and a $2.5+ billion run rate.

• Reinvests free cash from commercial success into R&D, enabling pipeline growth.

• Emphasizes data-driven prioritization and aggressive resource allocation for pipeline advancement.

• Pursues external opportunities selectively, focusing on late-stage GU or GI oncology assets.

Cabozantinib developments and market outlook

• CABINET study showed significant PFS improvement in advanced neuroendocrine tumors, leading to sNDA acceptance.

• Updated CABINET results to be presented at ESMO, with approval targeted for early 2025.

• High prescriber familiarity (75%-80%) with cabozantinib in NETs expected to ease adoption upon approval.

• Incremental launch investments planned, leveraging existing sales force and marketing infrastructure.

• CONTACT-02 in mCRPC showed PFS benefit but not statistically significant OS; sNDA submission planned.

Zanzalitinib (Zanza) pipeline and pivotal trials

• Zanza is a next-generation TKI with a shorter half-life and potential for improved tolerability.

• Four pivotal trials ongoing or planned: STELLAR-303 (CRC), STELLAR-304 (non-clear cell RCC), STELLAR-305 (head and neck), and STELLAR-311 (NETs).

• Early data suggest Zanza may rescue patients refractory to cabozantinib and could be first oral therapy in NETs.

• Collaboration with Arcus on STELLAR-009 is winding down; focus remains on Zanza's franchise potential.

• 2025 expected to be a pivotal year for Zanza, with key data readouts anticipated.